|
||||||||||||||||||
|
|
||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||
Questions? Please consult our answers to frequently asked questions at http://www.ebioscience.com/faq. DescriptionThe DJR4-1 monoclonal antibody reacts with human Decoy receptor 2 (DcR2), a transmembrane cell surface protein also known as TRAIL-R4 and TRUNDD. DcR2 has an extracellular TRAIL binding domain and a truncation in the death domain (DD) of its cytoplasmic tail. Along with DcR1, DcR2 binds to TRAIL and inhibits binding of TRAIL to DR4 or DR5 protecting cells from TRAIL-mediated cytotoxicity. DcR2 is expressed in many normal human tissues at low levels, but not in most tumors. Overexpression of DcR2 attenuates TRAIL-induced apoptosis. Applications ReportedFor research use only, not for diagnostic or therapeutic use. The DJR4-1 antibody has been reported for use in flow cytometric analysis. Applications TestedThe DJR4-1 antibody has been pre-titrated and tested by flow cytometric analysis of DcR2/293 transient transfected cells. This can be used at 20 μl (1 μg) per million cells in a 100 μl total staining volume. References
Gomez-Benito M, Martinez-Lorenzo MJ et al. 2007. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res. 2007 Jul 1;313(11):2378-88. (FC, PubMed) Mulherkar N, Prasad KV et al. 2007. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. J Biol Chem. 2007 Apr 20;282(16):11715-21. (FC, PubMed) Related ProductsCat. 12-4714 Phycoerythrin (PE) Mouse IgG1, K Isotype Control |
|||||||||||||||||||||||||||||||||||||||||||||
![]() |
![]() |
|
Copyright © 2000-2008 eBioscience, Inc. Product For Research Use Only: Not for further distribution without written consent. |